Tandem Diabetes Care Prices Upsized Private Placement of $275.0 Million of Convertible Senior Notes Due 2029

Rhea-AI Summary

Tandem Diabetes Care, Inc. (TNDM) announces the pricing of $275.0 million aggregate principal amount of 1.50% Convertible Senior Notes due 2029 in a private placement to qualified institutional buyers. The offering was upsized from $250.0 million, with an option for additional notes. The net proceeds are estimated to be around $266.3 million, to be used for various purposes including capped call transactions and repurchasing existing notes and common stock.

Positive

• None.

Negative

• The offering of the notes is not contingent upon the repurchase of the 2025 notes.
• The notes and shares of common stock upon conversion have not been registered under the Securities Act or state securities laws, limiting their sale in the United States without registration or exemption.

Insights

Financial Analyst

The announcement by Tandem Diabetes Care, Inc. regarding the upsized offering of convertible senior notes is a significant financial move that warrants attention from investors and market analysts. The increase from $250 million to $275 million, with an additional option for purchasers to acquire up to $41.25 million more, indicates a strong demand for the company's debt instruments, which may reflect positively on investor confidence in Tandem's financial health and future prospects.

Convertible notes are a hybrid financial instrument offering both the benefits of debt and the potential upside of equity conversion. The interest rate of 1.50% is relatively low, suggesting that Tandem is able to borrow at favorable terms, possibly due to a solid credit standing. This strategic financial maneuver allows Tandem to manage its capital structure efficiently by repurchasing existing 2025 notes, which could be a move to reduce interest expenses or to avoid dilution from those notes converting to equity.

The use of proceeds to repurchase common stock is also noteworthy. This action can be interpreted as the company signaling that its stock is undervalued or as a method to provide support to its stock price. However, the impact on the stock's market price and the dilutive effect of the conversion of these new notes into equity are critical factors to consider. The capped call transactions are designed to offset potential dilution, yet they introduce a level of complexity to the company's financial strategy that requires careful analysis.

Legal Expert

The legal implications of Tandem's offering, being conducted as a private placement under Rule 144A, are particularly relevant for institutional investors. This rule allows for the sale of securities to qualified institutional buyers without the need for a public offering, thus streamlining the process and potentially reducing regulatory overhead. However, it also limits the liquidity of the notes, as they cannot be immediately sold to the general public.

Furthermore, the convertible notes are being issued as unsecured obligations, which means they do not have collateral backing and are subordinate to secured debt in case of liquidation. This presents a higher risk for note holders, which is typically compensated by a higher interest rate, though in this case, the rate is low, potentially due to Tandem's creditworthiness.

The conversion feature and the associated capped call transactions are complex legal arrangements that require thorough understanding to assess their implications for both the company and the note holders. These mechanisms are put in place to manage the potential dilution of equity and to stabilize the company's capital structure, but they also add layers of legal and financial complexity that must be navigated with expertise.

Market Research Analyst

From a market perspective, Tandem's actions could be interpreted as a strategic pivot to optimize its capital allocation and to prepare for future growth initiatives. The repurchase of the 2025 notes and common stock indicates a proactive approach to managing the company's debt profile and equity base. This could be a response to market conditions or part of a broader strategic initiative to strengthen the balance sheet.

The timing and size of the offering, as well as the decision to enter into capped call transactions, suggest that Tandem is looking to minimize the impact of equity dilution on existing shareholders while still taking advantage of the current market conditions to secure long-term financing. The repurchase of common stock in conjunction with the offering could be seen as a move to consolidate ownership and could potentially be a positive signal to the market about the company's valuation.

It is also important to consider the potential market impact of the hedging and unwinding activities by the option counterparties and note holders. Such activities can lead to increased volatility in the company's stock price, which stakeholders should monitor closely. The overall market reaction to this news will depend on investor sentiment regarding Tandem's growth prospects and the perceived risk of the newly issued convertible notes.

SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced today the pricing of $275.0 million aggregate principal amount of 1.50% Convertible Senior Notes due 2029 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from the previously announced offering size of $250.0 million aggregate principal amount of notes. Tandem also granted the initial purchasers of the notes an option to purchase, within the 13-day period beginning on, and including, the first date on which the notes are issued, up to an additional $41.25 million aggregate principal amount of notes from Tandem. The sale of the notes is expected to close on March 8, 2024, subject to customary closing conditions.

The notes will be general unsecured obligations of Tandem and will accrue interest payable semiannually in arrears on March 15 and September 15 of each year, beginning on September 15, 2024, at a rate of 1.50% per year. The notes will mature on March 15, 2029, unless earlier converted, redeemed or repurchased.

Tandem estimates that the net proceeds from the offering will be approximately $266.3 million (or approximately $306.4 million if the initial purchasers exercise their option to purchase additional notes in full), after deducting the initial purchasers’ discounts and commissions and estimated offering expenses payable by Tandem. Tandem expects to use the net proceeds from the offering, together with cash on hand, to (i) pay the approximately $13.8 million cost of the capped call transactions that it entered into as described below, (ii) repurchase for cash approximately $246.7 million in aggregate principal amount of its 1.50% Convertible Senior Notes due 2025 (the “2025 notes”) in privately negotiated transactions entered into concurrently with the pricing of the notes in the offering and (iii) repurchase approximately $30.0 million of common stock in privately negotiated transactions entered into concurrently with the pricing of the notes in the offering through one of the initial purchasers or its affiliate from purchasers of the notes in the offering. If the initial purchasers exercise their option to purchase additional notes, Tandem expects to use a portion of the net proceeds from the sale of the additional notes to enter into additional capped call transactions and the remainder for general corporate purposes, which may include additional repurchases of the 2025 notes from time to time following the offering, or the repayment at maturity, of the 2025 notes.

Before December 15, 2028, holders will have the right to convert their notes only upon the satisfaction of specified conditions and during certain periods. On or after December 15, 2028 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their notes at any time. Upon conversion, Tandem will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The conversion rate for the notes will initially be 28.9361 shares of Tandem’s common stock per $1,000 principal amount of notes (equivalent to an initial conversion price of approximately $34.56 per share of Tandem’s common stock). The initial conversion price represents a premium of approximately 27.5% over the last reported sale price of $27.105 per share of Tandem’s common stock on March 5, 2024. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued or unpaid interest.

Tandem may not redeem the notes prior to March 22, 2027. Tandem may redeem for cash all or any portion of the notes (subject to certain limitations), at its option, on or after March 22, 2027 if the last reported sale price of Tandem’s common stock has been at least 130% of the conversion price for the notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which Tandem provides notice of redemption at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. However, Tandem may not redeem less than all of the outstanding notes unless at least $75.0 million aggregate principal amount of notes are outstanding and not called for redemption as of the time Tandem sends the related notice of redemption. No sinking fund is provided for the notes.

If Tandem undergoes a “fundamental change” (as defined in the indenture that will govern the notes), then, subject to certain conditions and limited exceptions, holders may require Tandem to repurchase for cash all or any portion of their notes at a fundamental change repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, following certain corporate events that occur prior to the maturity date or if Tandem delivers a notice of redemption, Tandem will, in certain circumstances, increase the conversion rate for a holder who elects to convert its notes in connection with such a corporate event or convert its notes called (or deemed called) for redemption in connection with such notice of redemption, as the case may be.

In connection with the pricing of the notes, Tandem entered into privately negotiated capped call transactions with one or more of the initial purchasers or their respective affiliates and certain other financial institutions (the “option counterparties”). The capped call transactions cover, subject to customary adjustments, the number of shares of Tandem’s common stock initially underlying the notes. The capped call transactions are expected to offset the dilution to Tandem’s common stock as a result of any conversion of the notes, with such offset subject to a cap. The cap price of the capped call transactions relating to the notes will initially be $42.0128, which represents a premium of approximately 55.0% over the last reported sale price of Tandem’s common stock on the Nasdaq Global Market on March 5, 2024, and is subject to certain adjustments under the terms of the capped call transactions.

In connection with establishing their initial hedges of the capped call transactions, Tandem expects that the option counterparties or their respective affiliates will enter into various derivative transactions with respect to Tandem’s common stock and/or purchase shares of Tandem’s common stock concurrently with or shortly after the pricing of the notes, including with, or from, certain investors in the notes. This activity could increase (or reduce the size of any decrease in) the market price of Tandem’s common stock or the notes at that time.

In addition, Tandem expects that the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to Tandem’s common stock and/or purchasing or selling shares of Tandem’s common stock or other securities of Tandem in secondary market transactions following the pricing of the notes and prior to the maturity of the notes (and are likely to do so during the observation period relating to any conversion of the notes on or after December 15, 2028 that is not in connection with a redemption, or, to the extent Tandem elects to unwind a portion of the capped call transactions, following any repurchase, redemption, exchange or early conversion of the notes). This activity could also cause or avoid an increase or a decrease in the market price of Tandem’s common stock or the notes, which could affect a noteholder’s ability to convert its notes and, to the extent the activity occurs following conversion or during any observation period related to a conversion of notes, it could affect the amount and value of the consideration that a noteholder will receive upon conversion of such notes.

Concurrently with the pricing of the notes in the offering, Tandem entered into privately negotiated transactions with certain holders of the 2025 notes to repurchase, for approximately $246.1 million in cash, approximately $246.7 million aggregate principal amount of its 2025 notes, excluding accrued and unpaid interest on the 2025 notes, on terms negotiated with each holder (each, a "note repurchase transaction"). This press release is not an offer to repurchase the 2025 notes, and the offering of the notes is not contingent upon the repurchase of the 2025 notes.

In connection with any note repurchase transaction, Tandem expects that holders of the 2025 notes who agree to have their 2025 notes repurchased and who have hedged their equity price risk with respect to such notes (the “hedged holders”) will unwind all or part of their hedge positions by buying Tandem’s common stock and/or entering into or unwinding various derivative transactions with respect to Tandem’s common stock. The amount of Tandem’s common stock to be purchased by the hedged holders or in connection with such derivative transactions may have been substantial in relation to the historical average daily trading volume of Tandem’s common stock. This activity by the hedged holders could increase (or reduce the size of any decrease in) the market price of Tandem’s common stock, including concurrently with the pricing of the notes, and may have resulted in a higher effective conversion price of the notes.

Additionally, in connection with the issuance of the 2025 notes, Tandem entered into capped call transactions (the “existing option transactions”) with certain financial institutions (the “existing option counterparties”). In connection with the note repurchase transactions, Tandem entered into agreements with the existing option counterparties to terminate a portion of the existing option transactions in a notional amount corresponding to the amount of 2025 notes repurchased (such terminations, the “unwind transactions”). In connection with such terminations of the existing option transactions, Tandem expects such existing option counterparties and/or their respective affiliates will unwind various derivatives with respect to Tandem’s common stock and/or sell shares of Tandem’s common stock concurrently with or shortly after pricing of the notes. This activity could decrease (or reduce the size of any increase in) the market price of Tandem’s common stock at that time and could decrease (or reduce the size of any increase in) the market value of the notes.

As discussed above, Tandem also intends to use approximately $30.0 million of the net proceeds from the offering to repurchase shares of its common stock. Tandem expects to repurchase such shares from purchasers of notes in the offering in privately negotiated transactions with or through one of the initial purchasers or its affiliate concurrently with the pricing of the offering (the “share repurchases”) at a purchase price per share of Tandem’s common stock equal to the closing price per share of Tandem’s common stock on March 5, 2024, which was $27.105 per share. These share repurchases could increase, or reduce the size of any decrease in, the market price of Tandem’s common stock, including concurrently with the pricing of the notes, and could have resulted in a higher effective conversion price for the notes. This press release is not an offer to repurchase Tandem’s common stock, and the offering of the notes is not contingent upon the repurchase of Tandem’s common stock.

The notes and any shares of Tandem’s common stock issuable upon conversion of the notes have not been and will not be registered under the Securities Act, any state securities laws or the securities laws of any other jurisdiction, and unless so registered, may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and other applicable securities laws.

This press release is neither an offer to sell nor a solicitation of an offer to buy any of these securities nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification thereof under the securities laws of any such state or jurisdiction.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. Tandem’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California.

Tandem Diabetes Care, the Tandem logo, Control-IQ, Tandem Mobi and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries.

Forward-looking Statements

This press release includes forward-looking statements regarding, among other things, the offering, including statements regarding the closing of the offering of the notes, capped call transactions, repurchase transactions and unwind transactions, the expected use of proceeds from the offering, the amount of repurchases of our 2025 notes and shares of our common stock, the potential impact of the foregoing or related transactions on dilution to holders of our common stock and the market price of our common stock or the notes. Any statement describing our expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including, without limitation, changes in market conditions, whether we will be able to satisfy closing conditions related to the offering, whether and on what terms we may repurchase any of the 2025 notes or shares of our common stock, whether the capped call transactions will become effective, whether the unwind transactions will become effective and unanticipated uses of capital, any of which could differ or change based upon market conditions or for other reasons. Tandem’s forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Tandem’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Tandem. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks are described in additional detail in Tandem’s annual report on Form 10-K for the year ended December 31, 2023, which is on file with the Securities and Exchange Commission.

In this press release, unless the context requires otherwise, “Tandem,” “Tandem Diabetes Care,” “we,” “our,” and “us” refers to Tandem Diabetes Care, Inc. and its subsidiaries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240305597839/en/

Tandem Investor Contact:

858-366-6900

IR@tandemdiabetes.com

Source: Tandem Diabetes Care, Inc.

FAQ

What is the ticker symbol of Tandem Diabetes Care, Inc.?

The ticker symbol of Tandem Diabetes Care, Inc. is TNDM.

What is the purpose of the $275.0 million aggregate principal amount of 1.50% Convertible Senior Notes due 2029 offering?

The purpose of the offering is to raise funds for Tandem Diabetes Care, Inc. to use for capped call transactions, repurchasing existing notes, and common stock.

When is the expected closing date of the sale of the notes?

The sale of the notes is expected to close on March 8, 2024, subject to customary closing conditions.

What is the interest rate on the notes?

The notes will accrue interest payable semiannually at a rate of 1.50% per year.

What is the expected net proceeds from the offering?

Tandem estimates the net proceeds to be approximately $266.3 million after deducting discounts, commissions, and offering expenses.

How will Tandem use the net proceeds from the offering?

Tandem plans to use the net proceeds for various purposes, including paying costs of capped call transactions, repurchasing existing notes, and common stock.

What is the conversion rate for the notes?

The initial conversion rate will be 28.9361 shares of Tandem's common stock per $1,000 principal amount of notes.

Can Tandem redeem the notes before March 22, 2027?

Tandem may not redeem the notes prior to March 22, 2027.

What happens if Tandem undergoes a 'fundamental change'?

Holders may require Tandem to repurchase their notes at a fundamental change repurchase price.

Are the notes and shares of common stock upon conversion registered under the Securities Act?

No, they have not been registered, limiting their sale in the United States without registration or exemption.